Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 3Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Prostatic Neoplasms 9Glioblastoma 9Carcinoma, Non-Small-Cell Lung 7Lung Neoplasms 6Brain Neoplasms 6Glioma 5Breast Neoplasms 5Oligodendroglioma 4Neoplasm Metastasis 4Multiple Myeloma 4Colorectal Neoplasms 4Astrocytoma 4Squamous Cell Carcinoma of Head and Neck 3Pancreatic Neoplasms 3Neuroectodermal Tumors, Primitive 3Neoplasms 3Meningioma 3Medulloblastoma 3Gliosarcoma 3Glioma, Subependymal 3Ependymoma 3Central Nervous System Neoplasms 3Carcinoma, Renal Cell 3Sarcoma 2Platinum-Refractory Fallopian Tube Carcinoma 2Pinealoma 2Melanoma 2Lymphoma, Mantle-Cell 2Lymphoma 2Hematologic Neoplasms 2

Interventions

trametinib 2olaparib 1glembatumumab vedotin 1durvalumab 1cediranib 1Vorinostat 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1CTLA-4 Antigen 1CR011-vcMMAE 1Biopsy, Fine-Needle 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Uveal Melanoma × Magnetic Resonance Spectroscopy × Clear all
NCT05677373 2023-08-18

Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma

Alliance for Clinical Trials in Oncology

Phase 1/2 Withdrawn
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡